T-cell receptor peptide therapy in EAE and MS

A. A. Vandenbark, D. N. Bourdette, R. Whitham, Y. K. Chou, G. A. Hashim, H. Offner

Research output: Contribution to journalArticlepeer-review


Synthetic peptides corresponding to germline TCR Vβ8.2 sequences overexpressed by Lewis rat encephalitogenic T cells are effective in the prevention and treatment of autoimmune encephalomyelitis (EAE). In evaluating optimal conditions for identifying disease-relevant target Vβ genes, we found that the biased expression of Vβ8.2 was most pronounced in the CNS among activated, IL-2 responsive T cells, but was weakly reflected in the cerebrospinal fluid. Evaluation of basic protein reactive T cells from patients with multiple sclerosis revealed biased expression of Vβ5.2 and to a lesser degree, Vβ6.1. Treatment of 11 MS patients with synthetic TCR Vβ5.2 and Vβ6.1 CDR2 peptides boosted the frequency of anti-TCR reactive T cells in a majority of patients, without compromising recall immunity or causing side effects. TCR peptides may be useful in the treatment of human autoimmune diseases, providing that disease-relevant V genes can be identified.

Original languageEnglish (US)
Pages (from-to)S51-S53
JournalClinical and experimental rheumatology
Issue numberSUPPL. 8
StatePublished - 1993
Externally publishedYes

ASJC Scopus subject areas

  • Rheumatology
  • Immunology and Allergy
  • Immunology


Dive into the research topics of 'T-cell receptor peptide therapy in EAE and MS'. Together they form a unique fingerprint.

Cite this